To identify markers of PD-1/PD-L1 blockade resistance and recapitulate the unresponsiveness of late-stage disease to therapy, we subcutaneously implanted immunosuppressive 344SQ KP murine lung cancer cells with high levels of PD-L112 into syngeneic immunocompetent wild-type (WT) mice, and treated mice weekly with anti-PD-L1 antibody 7 days post-implantation, as previously described8,12, or 21 days post-implantation when tumors were ~150–200 mm3 in size (Fig. 1a). Here, CD274 is linked to lung cancer.